Compare PNTG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | NTLA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 986.9M |
| IPO Year | N/A | 2016 |
| Metric | PNTG | NTLA |
|---|---|---|
| Price | $29.23 | $9.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | ★ $35.33 | $19.83 |
| AVG Volume (30 Days) | 249.5K | ★ 3.6M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $847,274,000.00 | $57,528,000.00 |
| Revenue This Year | $36.69 | $1.96 |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | $38.88 | ★ N/A |
| Revenue Growth | 29.89 | ★ 33.52 |
| 52 Week Low | $21.18 | $5.90 |
| 52 Week High | $30.46 | $28.25 |
| Indicator | PNTG | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 47.26 |
| Support Level | $28.99 | $8.74 |
| Resistance Level | $29.91 | $9.85 |
| Average True Range (ATR) | 0.68 | 0.47 |
| MACD | -0.14 | 0.30 |
| Stochastic Oscillator | 38.19 | 70.25 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.